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Summary
Background Secondary distribution of HIV self-testing (HIVST) kits by patients attending clinic services to their 
partners could improve the rate of HIV diagnosis. We aimed to investigate whether secondary administration of 
HIVST kits, with or without an additional financial incentive, via women receiving antenatal care (ANC) or via people 
newly diagnosed with HIV (ie, index patients) could improve the proportion of male partners tested or the number of 
people newly diagnosed with HIV.
Methods We did a three-arm, open-label, pragmatic, cluster-randomised trial of 27 health centres (clusters), eligible if 
they were a government primary health centre providing ANC, HIV testing, and ART services, across four districts of 
Malawi. We recruited women (aged ≥18 years) attending their first ANC visit and whose male partner was available, 
not already taking ART, and not already tested for HIV during this pregnancy (ANC cohort), and people (aged 
≥18 years) with newly diagnosed HIV during routine clinic HIV testing who had at least one sexual contact not 
already known to be HIV-positive (index cohort). Centres were randomly assigned (1:1:1), using a public selection of 
computer-generated random allocations, to enhanced standard of care (including an invitation for partners to attend 
HIV testing services), HIVST only, or HIVST plus a US$10 financial incentive for retesting. The primary outcome for 
the ANC cohort was the proportion of male partners reportedly tested, as ascertained by interview with women in this 
cohort at day 28. The primary outcome for the index cohort was the geometric mean number of new HIV-positive 
people identified per facility within 28 days of enrolment, as measured by observed HIV test results. Cluster-level 
summaries compared intervention with standard of care by intention to treat. This trial is registered with ClinicalTrials.
gov, NCT03705611.
Findings Between Sept 8, 2018, and May 2, 2019, nine clusters were assigned to each trial arm, resulting in 4544 eligible 
women in the ANC cohort (1447 [31·8%] in the standard care group, 1465 [32·2%] in the HIVST only group, and 
1632 [35·9%] in HIVST plus financial incentive group) and 708 eligible patients in the index cohort (234 [33·1%] in 
the standard care group, 169 [23·9%] in the HIVST only group, and 305 [42·9%] in the HIVST plus financial incentive 
group). 4461 (98·2%) of 4544 eligible women in the ANC cohort and 645 (91·1%) of 708 eligible patients in the 
index cohort were recruited, of whom 3378 (75·7%) in the ANC cohort and 439 (68·1%) in the index cohort were 
interviewed after 28 days. In the ANC cohort, the mean proportion of reported partner testing per cluster 
was 35·0% (SD 10·0) in the standard care group, 73·0% in HIVST only group (13·1, adjusted risk ratio [RR] 1·71, 
95% CI 1·48–1·98; p<0·0001), and 65·2% in the HIVST plus financial incentive group (11·6, adjusted RR 1·62, 
1·45–1·81; p<0·0001). In the index cohort, the geometric mean number of new HIV-positive sexual partners per 
cluster was 1·35 (SD 1·62) for the standard care group, 1·91 (1·78) for the HIVST only group (incidence rate 
ratio adjusted for number eligible as an offset in the negative binomial model 1·65, 95% CI 0·49–5·55; p=0·3370), 
and 3·20 (3·81) for the HIVST plus financial incentive group (3·11, 0·99–9·77; p=0·0440). Four self-resolving, 
temporary marital separations occurred due to disagreement in couples regarding HIV self-test kits.
Interpretation Although administration of HIVST kits in the ANC cohort, even when offered alongside a financial 
incentive, did not identify significantly more male patients with HIV than did standard care, out-of-clinic options for 
HIV testing appear more acceptable to many male partners of women with HIV, increasing test uptake. Viewed in the 
current context, this approach might allow continuation of services despite COVID-19-related lockdowns.
Funding Unitaid, through the Self-Testing Africa Initiative.
Copyright © 2021 World Health Organization; licensee Elsevier. This is an Open Access article published under the 
CC BY 3.0 IGO license.
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Introduction
Testing plays a key role in control of infectious diseases, 
including HIV, and it is crucial for diagnosis, treatment, 
and prevention. Men aged 30 years and older, adolescents, 
the most economically disadvantaged people, and key 
populations (eg, men who have sex with men, sex 
workers, etc) have a high risk of undiagnosed HIV, and 
they report facing substantial barriers to standard facility-
based HIV testing services.1 HIV self-testing (HIVST) 
provides a convenient, intrinsically confidential, and 
often preferred testing approach that can bypass facility 
access barriers, such as high indirect and opportunity 
costs, worries about confidentiality or reliability of routine 
services, and anticipated stigma.2 HIVST was fully 
endorsed by WHO as a recommended approach to 
providing HIV testing services in November, 2019, and it 
is promoted as an important tool for reaching HIV 
elimination targets in all global regions by international 
disease control initia tives (eg, the US Agency for 
International Development–President’s Emergency Plan 
for AIDS Relief).1,3 HIVST also provides an evidence-
based option to maintain HIV testing services, despite 
disruption to routine service delivery from the COVID-19 
pandemic.1
Among the most promising HIVST delivery strategies 
is secondary distribution, whereby patients attending 
clinic services take kits home for their sexual partners.4–6 
Secondary distribution from antenatal care (ANC) 
clinics is safe,7 acceptable to both partners, and the only 
approach tried, to date, that results in high uptake of 
HIV testing by male partners of pregnant women,4–6 
which is a key component of strategies for eliminating 
paediatric HIV.8 Although less well defined, secondary 
distribution of HIVST kits also holds promise as an 
additional way to test the sexual partners of people with 
newly diagnosed HIV (so-called index testing).2 Index 
testing provides a high yield of newly diagnosed HIV-
positive people globally;9 however, this approach was 
only endorsed in 2016–19 by HIV programmes because 
of concerns around confidentiality, stigma, and the 
safety of index patients and their partners, as well as 
feasibility due to existing laws and policies, and limited 
resources to support providers with ongoing training, 
monitoring, and supervision.
Malawi is a country in southeast Africa that has 
a high HIV prevalence, with an estimated adult 
prevalence of 9·2%.10 Undiagnosed HIV and the 
incidence of new HIV infection in adults and neonates 
Research in context
Evidence before this study
We searched PubMed on March 15, 2021, with no language 
restrictions, for titles and abstracts published between 
Jan 1, 1980, and March 15, 2021, using the search terms: 
(“HIV self-testing”[Title/Abstract]) OR (“HIV self 
testing”[Title/Abstract]), and found 483 records. Women are 
far more likely to attend HIV clinics for testing than are men. 
Furthermore, pregnancy is a period of high risk for 
HIV acquisition and transmission for fetuses and for sexual 
partners. Partner testing during pregnancy is recommended 
by WHO and is part of national guidelines, but 
implementation and uptake remains minimal. Studies in 
Malawi and Kenya have found increased uptake of testing 
among male partners of pregnant women when kits are 
offered in antenatal care; however, these studies have been 
done outside of real-world settings and have collected data 
on few outcomes. Previous studies on HIV self-testing 
(HIVST) among index partners have been limited to partners 
of patients receiving antiretroviral therapy who were 
recruited from outpatient facilities in Malawi. One such study 
found increased uptake of testing but poor linkage to care 
following HIVST implementation and, despite generally good 
acceptability of these tests, men aged 30 years and older 
reported challenges doing the test.
Added value of this study
Unlike previous studies that were implemented by research 
staff, in this study we show that it is feasible to integrate 
distribution of HIVST kits and management of clients with 
government personnel. Secondary distribution of HIVST kits by 
pregnant women or index patients to their male partners or 
sexual contacts improved uptake of testing in a pragmatic 
setting, which adds novelty relative to previous work. 
Although we found no significant difference in the numbers of 
new HIV diagnoses, our study extends knowledge on novel 
strategies for contact tracing and testing for newly diagnosed 
clinic attendees who are HIV-positive (so-called index testing).
Implications of all the available evidence
Our results show that secondary distribution of HIVST kits is 
an effective strategy that can support targeting of hard-to-
reach groups, such as men and sexual contacts of HIV-positive 
patients. We show that secondary distribution of HIVST kits 
can be readily integrated into routine clinic activities with few 
adverse events; therefore, they should now be considered 
regional priority. The results suggest an urgent need to 
optimise materials to enable users to get correct results under 
secondary distribution, especially in poor rural communities. 
In any case, novel strategies for maintaining HIV services are 
needed during the COVID-19 pandemic, and approaches based 
on HIVST have the major advantage of not requiring direct 
interaction between contacts and providers until confirmatory 
testing and enrolment into HIV care. HIVST can meet unique 
programmatic needs and global HIV testing targets, both 
during the COVID-19 pandemic and in the long term, and 
should be implemented routinely in all settings with high 
HIV prevalence.
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have been substantially reduced by a highly efficient 
and pragmatic HIV testing and antiretroviral therapy 
(ART) programme, with an estimated 90·0% of people 
living with HIV diagnosed and 87·0% of those receiving 
ART in 2018.10 Nevertheless, providing HIV testing to 
male partners of pregnant women during pregnancy 
has remained an important gap, contributing to new 
HIV infections in pregnant and breastfeeding women 
that now account for a high proportion of all perinatal 
HIV infections in Malawi.11 Index testing has been 
routinely implemented by use of patient referral or an 
invitation by letter (eg, family referral slip) for all 
partners and family members of people with newly 
diagnosed HIV to attend for HIV testing, without 
further active follow-up.12
Financial incentives address economic barriers 
associated with HIV testing and care, including direct 
and opportunity costs, especially for men.13 A growing 
body of literature suggests that the use of financial 
incentives increases HIV testing and clinic attendance 
for HIV services, including ART initiation, especially 
in hard-to-reach groups such as men.4,14 However, in 
resource-limited settings with heightened amounts of 
corruption, few delivery platforms, and personal risk to 
staff, use of financial incentives is largely unsupported by 
policy makers.
In this study, set in Malawi, we aimed to investigate 
whether secondary administration of HIVST kits, in the 
presence or absence of an additional financial incentive, 
via women receiving ANC could improve the proportion 
of male partners being tested. We also aimed to 
investigate whether secondary administration of these 
test kits, with or without a financial incentive, via people 
who had been newly diagnosed with HIV (ie, index 
patients) could improve the number of people newly 
diagnosed with HIV. 
Methods
Study design and participants
We did a three-arm, open-label, pragmatic, cluster-
randomised trial of 27 government health centres 
(clusters) across four districts (Blantyre, Zomba, Thyolo, 
and Mulanje) of Malawi. Centres were eligible to be a 
cluster if they were a government primary health clinic 
or centre providing ANC, HIV testing, and ART services. 
The minimum distance between any two clusters was 
5 km, which substantially reduced or eliminated any 
potential contamination. Each cluster enrolled women 
attending ANC (ANC cohort) and people with newly 
diagnosed HIV during routine clinic HIV testing 
(index cohort) into one of three trial arms (standard of 
care, HIVST only, and HIVST plus financial incentive). 
Each health centre recruited participants for both 
cohorts. HIVST kits were provided by routine health 
staff after verbal consent was obtained, given that all 
components were already national policy. Leaflets for 
recipients explained that data would be used for a 
research study. Written informed consent was obtained 
from all participants within clusters assigned to the 
HIVST plus financial incentive group, as well as their 
sexual partners, who all took part in a diagnostic 
accuracy substudy. Ethics approval was obtained 
from the Malawi College of Medicine Research Ethics 
Committee (P.02/18/2352) and London School of 
Hygiene & Tropical Medicine Ethics Committee (14916). 
Although there is potential for harm resulting from 
false positive or false negative HIVST results and 
coercion, the evidence indicates negligible social harms 
from introducing HIVST.7,15
Eligible women attending ANC were enrolled into the 
ANC clinic cohort unless newly diagnosed with HIV, in 
which case they would be enrolled into the index cohort. 
Depending on the trial arm they were assigned to, 
women were provided with materials and brief training 
for their male partner, assuming only one probable 
father. We included women who were attending their 
first ANC visit; aged at least 18 years; intending to remain 
in the clinic catchment area; not already enrolled; and 
whose male partner (ie, the child’s probable father) was 
present and reachable, not already receiving ART, or not 
already tested during this pregnancy. We excluded 
women if their male partner was aged younger than 
18 years, already receiving ART, and not presently 
available and resident in the catchment area.
People newly diagnosed with HIV during routine clinic 
HIV testing, including pregnant women, were enrolled 
into the index cohort. We included individuals who 
were aged at least 18 years, intending to remain in the 
clinic catchment area, not already enrolled, and had at 
least one sexual contact (ie, contactable sexual partner) 
not already known to be HIV-positive. We excluded 
index patients if all of their sexual contacts were aged 
younger than 18 years or were already receiving ART, or 
if none were presently available and resident in the 
catchment area. Depending on the trial arm they were 
assigned to, index patients were provided with materials 
and brief training, and asked to deliver materials to all 
sexual contacts over the past 12 months. The number of 
sexual contacts per index patient varied on the basis of 
the number of contactable sexual partners.
Randomisation and masking
Restricted randomisation (blocking) was used to 
randomise the 27 clusters to three arms in a ratio of 1:1:1, 
with district and HIV prevalence in ANC as the variables 
for restriction. The first group was enhanced standard of 
care (standard care group), which only offered letters 
inviting male partners or sexual contacts to attend 
HIV testing services at the clinic. The second group 
was HIVST only (HIVST only group), which offered 
invitation letters plus oral HIVST kits to the pregnant 
women to deliver to their male partners or to the 
index patients to deliver to their sexual contacts. The 
third group was HIVST with an additional financial 
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incentive (HIVST plus financial incentive group), 
which offered male partners or sexual contacts US$10 to 
retest at the clinic following self-testing, irrespective 
of HIV status. A statistician (MN) generated a list of 
100 000 randomisation options meeting the restriction 
criteria and chose one of these options at random using 
a computer programme. At a public ceremony held on 
June 29, 2018, representatives of the 27 primary health 
centres and hospitals were split into three groups 
according to the letters of their randomisation allocation. 
Each group chose a team name and a team captain. The 
team captains drew a golf ball at random, which was 
prelabelled with the trial arm to be implemented at the 
nine clinics within their group.
Due to the nature of the interventions, clinic personnel 
and participants could not be masked to allocation; 
however, data were managed by an appointed data 
manager without reference to the trial arm to maintain 
investigator masking until final analysis.
Procedures
In the standard care group, letters (ie, standard family 
referral slips) were used to invite male partners of women 
in the ANC cohort or sexual partners of patients in the 
index cohort to attend HIV testing services within 28 days 
of enrolment. The HIVST only group used the approach 
intended for routine adoption in Malawi, with only 
HIV-positive partners advised to return for confirmation 
and HIV care. The HIVST plus financial incentive group 
allowed the diagnostic accuracy of HIVST kits distributed 
in this way to be investigated. The participant’s own 
interpretation of HIVST results and results obtained from 
retesting by the HIV provider were compared. This group 
was also offered voluntary male medical circumcision 
(VMMC) for uncircumcised men who were HIV-negative.
In the HIVST only group, women in the ANC cohort 
or patients in the index cohort were provided with 
one OraQuick HIV Self-Test (OraSure Technologies, 
Bethlehem, PA, USA) kit per sexual partner for secondary 
distribution, with a brief demonstration (approximately 
5 min) on how to correctly open the kit, identify the 
instructions for use, run the test, and read the results. 
Partners were encouraged to attend clinic services to 
confirm all positive results or results that were 
serodiscordant (ie, one positive and one negative) with 
their regular partner.
In the HIVST plus financial incentive group, women 
in the ANC cohort or patients in the index cohort were, 
in addition to the test kit and demonstration, provided 
with a leaflet offering their male partner or sexual 
contacts $10 to retest at the clinic. Demand-side financial 
incentives (ie, incentives offered to users of health 
services) have become of interest in HIV, especially for 
increasing the uptake of testing and clinic attendance in 
priority populations.14
Government staff managed secondary HIVST kit 
distribution and HIV care, including confirmatory 
testing and starting patients on ART. Follow-up 
interviews with women in the ANC cohort were 
completed by an interviewer, independent from the 
original kit distributor, at the next ANC visit (within 
28 days) to ascertain male partner testing. There was no 
compensation for completing this interview.
Follow-up testing was done by accredited providers 
using two fingerprick rapid diagnostic tests in parallel 
(Determine [Abbott; Chicago, IL, USA] and Uni-Gold 
[Trinity Biotech; Bray, Ireland]) for all male partners or 
sexual contacts who collected their $10 incentive and 
reported having self-tested in the HIVST plus financial 
incentive group. HIVST results were self-reported, with 
inspection of used HIVST kits if brought by the client. 
Participants had to show a used HIVST kit; if the used 
HIVST was not available, the participant was asked to do 
a second HIVST before follow-up testing.
Outcomes
The primary outcome for the ANC cohort was 
the proportion of male partners reportedly tested for 
HIV, as ascertained by interview with the woman 
attending ANC 28 days after enrolment. The primary 
outcome for the index cohort was the geometric mean 
number of HIV-positive people diagnosed per cluster, 
within 28 days of enrolling the index patient. To satisfy 
the primary outcome, within 28 days of enrolling the 
index patient, a sexual contact of a participant in the 
standard care group had to present the originally 
allocated letter to the clinic and test positive, and a 
sexual contact of a participant in the HIVST only group 
and HIVST plus financial incentive group had to bring 
a positive self-test result to be immediately confirmed.
Secondary outcomes for the ANC cohort were the 
proportion of male partners attending any HIV clinic 
services, or who started ART, underwent VMMC, or 
attended a discordant couples’ clinic within 28 days of 
enrolling participants, using all eligible women as the 
denominator. A post-hoc analysis for this cohort was the 
proportion of male partners booked for VMMC, also 
using all eligible women as the denominator.
Secondary outcomes for the index cohort were the 
proportion of sexual contacts reportedly tested for HIV, as 
ascertained by interview with the index patient at day 28; 
the number of sexual contacts who attended the clinic for 
any HIV services; and the number of sexual contacts who 
started ART, underwent VMMC, or attended a discordant 
couples’ clinic, within 28 days of the index patient’s 
diagnosis. A secondary outcome for both cohorts was the 
percentage of adverse events (eg, partnership breakdown, 
intimate partner violence, etc) related to HIVST reported 
by participants, measured at day 28.
Outcomes were evaluated at day 28 by use of participant 
interviews and clinic registers, including phone calls for 
clients with missed interviews.
We also did a prespecified exploratory analysis of 
secondary accuracy of HIVST—the correctness (ie, 
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27 government health centres (clusters) 
assessed for eligibility 
ANC cohort
9939 women assessed for eligibility
Index cohort
1480 patients assessed for eligibility
ANC cohort
5395 women excluded for not meeting inclusion criteria
2499 attended with partner
1645 had a partner who was away
845 had a partner already receiving ART
281 aged <18 years
125 had no current partner
Index cohort
772 patients excluded for not meeting inclusion criteria
315 had a partner already receiving ART
180 had a partner who was away
106 not ready to discuss sexual contacts
102 tested together with partner
41 aged <18 years
28 had no current partner
9 clusters allocated to HIVST only 
group
ANC cohort
1165 women completed follow-up
Index cohort
117 patients completed follow-up 
0 clusters lost to follow-up
ANC cohort
285 women lost to follow-up
Index cohort
36 patients lost to follow-up 
9 clusters included in analysis
ANC cohort
1465 women included in primary 
analysis
Index cohort
169 patients included in primary 
analysis
ANC cohort
1465 women met inclusion criteria
1450 women recruited
15 did not give consent to
participate 
Index cohort
169 patients met inclusion criteria
153 patients recruited
16 did not give consent to
participate
9 clusters allocated to HIVST plus
financial incentive group
ANC cohort
1132 women completed follow-up
Index cohort
166 patients completed follow-up 
0 clusters lost to follow-up
ANC cohort
483 women lost to follow-up
Index cohort
122 patients lost to follow-up 
9 clusters included in analysis
ANC cohort
1632 women included in primary 
analysis
Index cohort
305 patients included in primary 
analysis 
ANC cohort
1632 women met inclusion criteria
1615 women recruited
17 did not give consent to
participate 
Index cohort
305 patients met inclusion criteria
288 patients recruited
17 did not give consent to
participate
9 clusters allocated to standard care 
group
ANC cohort
1081 women completed follow-up
Index cohort
156 patients completed follow-up 
9 clusters included in analysis
ANC cohort
1447 women included in primary 
analysis
Index cohort
234 patients included in primary 
analysis
ANC cohort
1447 women met inclusion criteria
1396 women recruited
51 did not give consent to
participate 
Index cohort
234 patients met inclusion criteria
204 patients recruited
30 did not give consent to
participate
0 clusters lost to follow-up
ANC cohort
315 women lost to follow-up
Index cohort
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sensitivity and specificity) with which the ultimate user 
(not necessarily the original recipient of the test kit) does 
the test—in the HIVST plus financial incentive group.
Statistical analysis
The sample size calculation was based on the primary 
outcome of the ANC cohort, with nine clusters per 
arm and 350 pregnant women per cluster, providing 
90% power to detect a 12% increase in partner HIV testing 
over an assumed 20% in the standard care group, using a 
coefficient of variation (k) of 0·25.4
ANC cohort analyses followed intention-to-treat 
principles, so all eligible women (not just those who 
participated) were included in the denominator.16 A per-
protocol post-hoc analysis16 was also done for the 
ANC cohort, excluding women not interviewed at follow-
up. The main hypothesis testing in the ANC cohort used 
cluster-level summaries and a t test due to the small 
number of clusters per arm, with methods appropriate 
for clustered trial designs.17 In summary, the proportion 
achieving the primary outcome was computed for each 
cluster. The mean of proportions in each intervention 
arm was then compared with the mean of proportions in 
the standard care group with a t test. Risk ratios (RRs), 
risk differences, and 95% CIs were computed for male 
partner testing. A sensitivity analysis using random-
effects logistic regression was done. For the primary 
outcome of the index cohort, analysis followed intention-
to-treat principles. The geometric mean count of 
HIV-positive contacts was calculated, with a negative 
binomial model used for incidence rate ratios (IRR) 
comparing each intervention group with the standard 
care group, to account for overdispersion.
Analyses for the secondary outcomes followed 
intention-to-treat principles, with all male partners or 
sexual contacts achieving the outcome in the numerator 
and all eligible women in the ANC cohort or eligible 
patients in the index cohort in the denominator.
As a sensitivity analysis, an individual-level, random-
effects logistic model was fitted for the ANC cohort to 
explore any potential differences from the main analysis.
To estimate secondary accuracy, the sensitivity and 
specificity and associated 95% CIs of participants’ own 
interpretation of self-test results were computed by use 
of HIV provider-administered parallel rapid testing, with 
Uni-Gold (Abbott) and Determine (Biotech) as the 
reference.
Statistical analysis was done with R (version 5.1) and 
Stata (14.0).
This trial is registered with ClinicalTrials.gov, 
NCT03705611.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
We completed this study between Sept 8, 2018, and 
May 2, 2019. In the ANC cohort, a total of 9939 women 
were assessed for eligibility, of whom 4544 (45·7%) were 
eligible (figure). 5395 (54·3%) women were excluded 
largely because they were accompanied by the male 
partner to the ANC visit. Nine clusters were randomly 
assigned to each group, resulting in 1447 (31·8%) of 
4544 women in the standard care group, 1465 (32·2%) in 
the HIVST only group, and 1632 (35·9%) in the HIVST 
















Women in the ANC cohort
Age, years 22 (19–28) 22 (19–27) 23 (19–33)
Able to read and write
Yes 1176 (81·3%) 1368 (93·4%) 1524 (93·4%)
No 247 (17·1%) 95 (6·5%) 104 (6·4%)
Data missing 24 (1·6%) 2 (0·1%) 4 (0·2%)
HIV test results before trial
Positive 16 (1·1%) 11 (0·8%) 13 (0·8%)
Negative 1415 (97·8%) 1452 (99·1%) 1617 (99·1%)
Data missing 16 (1·1%) 2 (0·1%) 2 (0·1%)
Intimate partner violence or adverse behaviour, or marital separation, 
in past 12 months
Physical violence 23 (1·6%) 6 (0·4%) 39 (2·4%)
Forced sex 0 1 (0·1%) 4 (0·3%)
Threatened 6 (0·4%) 3 (0·2%) 9 (0·5%)
Shouted at 33 (2·3%) 6 (0·4%) 59 (3·6%)
Ignored 14 (1·0%) 3 (0·2%) 10 (0·6%)
Marital separation 18 (1·2%) 3 (0·2%) 9 (0·5%)
Denied household 
needs
3 (0·2%) 0 6 (0·4%)
None 1280 (88·5%) 1434 (97·9%) 1490 (91·3%)
Data missing 70 (4·8%) 9 (0·6%) 6 (0·4%)
Male partners
Age, years 26 (22–32) 26 (22–33) 27 (23–33)
HIV testing history
Never tested before 409 (28·3%) 520 (35·6%) 422 (25·7%)
Tested >12 months 
ago
253 (17·6%) 443 (30·2%) 343 (21·1%)
Tested ≤12 months 
ago
263 (18·1%) 208 (14·2%) 556 (34·1%)
Unsure 345 (23·8%) 248 (16·7%) 245 (15·0%)
Data missing 177 (12·2%) 46 (3·1%) 66 (4·1%)
Data are median (IQR) or n (%). HIVST=HIV self-testing. ANC=antenatal care. 
Table 1: Characteristics of women in the ANC cohort and their male 
partners, as reported by these women at enrolment
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women did not consent to participate and were not 
recruited, but were still included in the analysis 
population: 51 (3·5%) of 1447 women in the standard of 
care group, 15 (1·0%) of 1465 in the HIVST only group, 
and 17 (1·0%) of 1632 in the HIVST plus financial 
incentive group. Of the 4461 women recruited, 
315 (22·6%) of 1396 individuals in the standard care 
group, 285 (17·6%) of 1615 individuals in the HIVST only 
group, and 483 (33·3%) of 1450 individuals in the HIVST 
plus financial incentive group were lost to follow-up at 
28 days. No cluster was lost to follow-up; hence, all 
clusters were included in the analysis and all eligible 
women were included in the analysis of the primary 
outcome.
In the index cohort, a total of 1480 index patients were 
assessed for eligibility, of whom 708 (47·8%) were 
eligible. We excluded 772 (52·2%) patients mostly due to 
their sexual contact already receiving ART. Nine clusters 
were randomly assigned to each group, resulting in 
234 (33·1%) patients in the standard care group, 
169 (23·9%) in the HIVST only group, and 305 (42·9%) 
in the HIVST plus financial incentive group. 63 (8·9%) 
of 708 eligible patients did not consent to participate and 
were not recruited, but were still included in the analysis 
population: 30 (12·8%) of 234 patients in the standard of 
care group, 16 (9·5%) of 169 in the HIVST only group, 
and 17 (5·6%) of 305 in the HIVST plus financial 
incentive group. Among the 645 index patients recruited, 
48 (23·5%) of 204 individuals in the standard care group, 
36 (23·5%) of 153 individuals in the HIVST only group, 
and 122 (42·4%) of 288 individuals in the HIVST plus 
financial incentive group were lost to follow-up at 
28 days. No clusters were lost to follow-up and were all 
included in the analysis, with all eligible index patients 
included in the analysis of the primary outcome.
Baseline characteristics of women in the ANC cohort 
were reasonably balanced (table 1), except for illiteracy 
(247 [17·1%] of 1447 in the standard care group vs 
95 [6·5%] of 1465 in the HIVST only and 104 [6·4%] of 
1632 in the HIVST plus financial incentive group) and 












Number of clusters 9 9 9
Harmonic mean number 
per cluster
90 138 136
Patients in the index cohort
Sex
Male 58 (24·8%) 36 (21·3%) 99 (32·5%)
Female 175 (74·8%) 132 (78·1%) 206 (67·5%)
Data missing 1 (0·4%) 1 (0·6%) 0
Age, years 27 (23–35) 28 (22–34) 30 (24–36)
Able to read and write
Yes 166 (70·9%) 144 (85·2%) 272 (89·2%)
No 59 (25·2%) 22 (13·0%) 27 (8·8%)
Data missing 9 (3·9%) 3 (1·8%) 6 (2·0%)
Intimate partner violence or adverse behaviour, or marital separation, 
in past 12 months
Physical violence 2 (0·9%) 1 (0·6%) 6 (2·0%)
Forced sex 0 0 1 (0·3%)
Threatened 1 (0·4%) 0 0
Shouted at 7 (3·0%) 1 (0·6%) 16 (5·3%)
Ignored 5 (2·1%) 0 4 (1·3%)
Marital separation 9 (3·9%) 1 (0·6%) 5 (1·6%)
Denied household 
needs
0 0 1 (0·3%)
None 199 (85·0%) 161 (95·3%) 259 (84·9%)
Data missing 11 (4·7%) 5 (3·0%) 13 (4·3%)
Number of sexual contacts in past 12 months
1 198 (84·6%) 153 (90·5%) 269 (88·2%)
2–4 24 (10·3%) 9 (5·3%) 32 (10·5%)
Data missing 12 (5·1%) 7 (4·2%) 4 (1·3%)
Number of sexual contacts still in contact with
1 209 (89·3%) 162 (95·8%) 284 (93·1%)
2–4 10 (4·3%) 3 (1·8%) 17 (5·6%)
Data missing 15 (6·4%) 4 (2·4%) 4 (1·3%)
Number of sexual contacts able to give letter or kits
1 209 (89·3%) 155 (91·7%) 285 (93·4%)
2–4 8 (3·4%) 3 (1·8%) 16 (5·3%)
Data missing 17 (7·3%) 11 (6·5%) 4 (1·3%)












(Continued from previous column)
Sexual contacts
Sex
Male 169 (72·2%) 132 (78·1%) 212 (69·5%)
Female 60 (25·6%) 34 (20·1%) 92 (30·2%)
Data missing 5 (2·2%) 3 (1·8%) 1 (0·3%)
Age, years 30 (26–37) 30 (25–37) 32 (26–37)
Testing together for HIV
Never tested before 124 (53·0%) 96 (56·8%) 161 (52·8%)
Tested >12 months ago 62 (26·5%) 33 (19·5%) 94 (30·8%)
Tested ≤12 months ago 37 (15·8%) 36 (21·3%) 47 (15·4%)
Data missing 11 (4·7%) 4 (2·4%) 3 (1·0%)
HIV status
Positive 10 (4·3%) 26 (15·4%) 12 (3·9%)
Negative 62 (26·5%) 19 (11·2%) 83 (27·2%)
Unknown 157 (67·1%) 121 (71·6%) 207 (67·9%)
Data missing 5 (2·1%) 3 (1·8%) 3 (1·0%)
Data are median (IQR) or n (%). HIVST=HIV self-testing.  
Table 2: Characteristics of patients in the index cohort and their sexual 
contacts, as reported by index patients at enrolment
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12 months  ago (516 [35·7%] of 1447 in the standard care 
group vs 651 [44·4%] of 1465 in the HIVST only group 
and 899 [55·1%] of 1632 in the HIVST plus financial 
incentive group).
For the index cohort, there was reasonable balance in 
baseline characteristics (table 2), although there were 
more men in the HIVST plus financial incentive group 
than in the HIVST only and standard care groups 
(99 [32·5%] of 305 vs 58 [24·8%] of 234 in the standard 
care group and 36 [21·3%] of 169 in the HIVST only 
group), and higher illiteracy in the standard care group 
(59 [25·2%] of 234) than in the HIVST only 
(22 [13·0%] of 169) and HIVST plus financial incentive 
(27 [8·8%] of 305) groups.
For the primary outcome in the ANC cohort, mean 
uptake per cluster of male partner HIV testing by 28 days, 
as reported by women in this cohort, was 73·0% 
(SD 13·1) in the HIVST only group and 65·2% (11·6) in 
the HIVST plus financial incentive group, compared 
with 35·0% (10·0) in the standard care group (table 3). 
In comparison with the standard care group, the adjus-
ted RR was 1·71 (95% CI 1·48–1·98, p<0·0001) for 
the HIVST only and 1·62 (1·45–1·81, p<0·0001) for 
the HIVST plus financial incentive groups (table 3; 
appendix p 1). The coefficient of variation (k) for the male 
partner testing outcome was 0·15.
For the primary outcome in the index cohort, the 
geometric mean number of new positive sexual partners 
per cluster was 1·35 (SD 1·62) for the standard care 
group, 1·91 (1·78) for the HIVST only group, and 
3·20 (3·81) for the HIVST plus financial incentive group 
(table 3; appendix p 2). The HIVST plus financial 
incentive group had a higher incidence of newly 
diagnosed HIV-positive sexual contacts than did the 
standard care group (IRR 3·24, 95% CI 1·16–9·07; 
p=0·0250); however, there was no difference in rates 
between the HIVST only group and the standard care 
group (IRR 1·38, 0·45–4·16; p=0·5660). In an analysis 
adjusted for number of eligible index patients per cluster 
(which was more highly variable or overdispersed than 
anticipated in our statistical analysis plan), the evidence 
for difference with the HIVST plus financial incentive 
intervention was weaker, with an adjusted IRR of 3·11 
(0·99–9·77; p=0·0440). The coefficient of variation (k) for 
the male partner testing outcome was 0·75.
Secondary outcomes in the ANC cohort should be 
interpreted in light of the different instructions given 
per arm—ie, all partners were asked to attend clinic 
HIV services in the standard care and HIVST plus 
financial incentive groups, yet only men testing positive 
with HIVST and serodiscordant couples were asked to 
attend HIV services in the HIVST only group. Thus, the 
main comparison for the proportion of male partners 
attending any HIV clinic services was the standard care 
group versus the HIVST plus financial incentive group 
(table 4). Providing HIVST plus $10 for clinic attendance 
substantially increased male partner attendance, from a 
mean of 19·7% (SD 7·6) per cluster in the standard care 
group to 76·5% (20·0) in the HIVST plus financial 
incentive group (adjusted RR 2·84, 95% CI 2·37–3·41; 
table 4). The proportion of male partners starting ART, 
undergoing VMMC, or attending discordant couples’ 
clinic was 168 (11·6%) of 1447 eligible women in the 
standard care group versus 309 (18·9%) of 1632 eligible 
women in the HIVST plus financial incentive group 
(p<0·0001; appendix p 3).
For the secondary outcomes in the index cohort, the 
mean proportion per cluster of eligible sexual partners 
reported by the index patients as having tested for HIV 
See Online for appendix
Standard care 
group
HIVST only group HIVST plus financial 
incentive group
Women in the ANC cohort and their male partners
Number of eligible women 1447 1465 1632
Number of male partners tested* 498 (34·4%) 1106 (75·5%) 1000 (61·3%)
Mean proportion per cluster, % (SD) 35·0% (10·0) 73·0% (13·1) 65·2% (11·6)
p value ·· <0·0001 <0·0001
Risk difference (95% CI) vs standard 
care
·· 38·3% (35·0–41·7) 30·1% (26·8–33·5)
Unadjusted RR (95% CI) 1 (ref) 2·08 (1·64–2·64) 1·86 (1·47–2·35)
p value ·· <0·0001 <0·0001
Adjusted RR† (95% CI) 1 (ref) 1·71 (1·48–1·98) 1·62 (1·45–1·81)
p value ·· <0·0001 <0·0001
Per-protocol analysis of women in the ANC cohort and their male partners
Number of women interviewed at 
follow-up
1081 1165 1132
Number of male partners tested* 498 (46·1%) 1106 (94·9%) 1000 (88·3%)
Mean proportion per cluster, % 48·7% 93·7% 89·1%
Risk difference (95% CI) vs standard 
care
·· 48·9% (41·2–56·5) 42·3% (33·7–50·8)
Unadjusted RR (95% CI) 1 (ref) 3·09 (2·52–3·65) 2·18 (1·66–2·71)
p value ·· <0·0001 <0·0001
Adjusted RR† (95% CI) 1 (ref) 3·04 (2·38–3·70) 2·07 (1·49–2·66)
p value ·· <0·0001 <0·0001
Patients in the index cohort and their sexual contacts
Number of eligible index patients 234 169 305
Number of sexual contacts reached by 
index patients
209 155 285
Number of sexual contacts testing 
HIV-positive‡
9/209 (4·3%) 13/155 (8·4%) 32/285 (11·2%)§
Geometric mean per cluster (SD) 1·35 (1·62) 1·91 (1·78) 3·20 (3·81)
Risk difference (95% CI) vs standard 
care
·· 4·3% (2·2–6·4) 6·9% (3·2–9·1)
Unadjusted incidence RR (95% CI) 1 (ref) 1·38 (0·45–4·16) 3·24 (1·16–9·07)
p value ·· 0·5660 0·0250
Adjusted incidence RR¶ (95% CI) 1 (ref) 1·65 (0·49–5·55) 3·11 (0·99–9·77)
p value ·· 0·3370 0·0440
Each trial arm had nine clusters. HIVST=HIV self-testing. ANC=antenatal care. RR=risk ratio. *Measured within 28 days, 
as reported by women in the ANC cohort at their next ANC visit (k=0·15). †Adjusted for woman’s literacy and male 
partner’s HIV testing history. ‡Extracted from clinic records and confirmed to be newly diagnosed as HIV-positive 
(k=0·75). §19 individuals from Mulanje District Hospital (Mulanje) and nine from Mbayani Primary Health Centre 
(Blantyre). ¶Adjusted for the number eligible as an offset in the negative binomial model. 
Table 3: Reported testing of male partners of women in the ANC cohort and newly diagnosed 
HIV-positive people among sexual contacts of patients in the index cohort
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within 28 days was higher in the HIVST only group and 
in the HIVST plus financial incentive group than in the 
standard care group (table 4). The number of sexual 
contacts attending the clinic for any HIV services was 
51 (21·8%) of 234 eligible patients in the standard care 
group, 17 (10·1%) of 169 in the HIVST only group, and 
181 (59·3%) of 305 in the HIVST plus financial incentive 
group. The number of sexual contacts who started ART, 
underwent VMMC, or attended discordant couples’ clinic 
was 60 (19·7%) of 305 individuals in the HIVST plus 
financial incentive group as per intention-to-treat 
analysis, compared with 12 (5·1%) of 234 in the standard 
care group and 16 (9·5%) of 169 in the HIVST only 
group.
Only four (0·1%) of the 5252 individuals combined 
reported a marital separation related to self-testing at the 
day 28 interview; two in the HIVST only group and two 
in the HIVST plus financial incentive group, both of 
which were from the ANC cohort. No other adverse 
events were reported.
In the ANC cohort, differences in the primary outcome 
between each trial arm were more pronounced in the 
per-protocol analysis (table 3). The highest reported 
HIV testing coverage was in the HIVST only group. 
Results from an individual-level, random-effects logistic 
model were similar to those obtained from the cluster-level 
summaries approach for the ANC cohort primary outcome 
of male partner testing within 28 days (data not shown).
Among 863 sexual partners retested in the HIVST 
plus financial incentive group of both cohorts, HIVST 
sensitivity was 89·7% (95% CI 78·8–96·1) with 52 of 
58 partners with HIV correctly identified through 
HIVST, and specificity was 99·5% (98·7–99·9), with 
801 of 805 partners correctly identified as not having 
HIV through HIVST. Of the 52 true-positive patients 
newly diagnosed by HIVST, 20 were partners of 
HIV-negative women attending ANC and 32 were sexual 
contacts of index patients. There were an additional 
six false-negative, four false-positive, and 807 true-
negative patients. All four false-positive results reflected 
misinterpretation of the kits showing negative results, 
whereas the six false-negative results were in patients 
with undetectable viral loads (<1000 copies per mL of 
blood).
In post-hoc analyses, we found that the proportion of 
male partners booked for VMMC among HIV-negative 
men (appendix p 3) and the proportion of male partners 
with new HIV diagnoses (table 4) were numerically 
higher in the HIVST plus financial incentive group than 
in the standard care group; however, the proportion of 
male partners booked for VMMC among all eligible 
women did not substantially differ between these 
two groups (table 4).
Discussion
This pragmatic, cluster-randomised trial showed that 
routinely offering oral HIVST kits through secondary 
distribution could be readily integrated into routine 
clinical practice in rural health centres and district 
hospitals, with high participation and minimal harms. 
Secondary distribution provided a highly acceptable 
out-of-clinic strategy that substantially increased HIV 
testing by male partners of pregnant women, confirming 
high potential to contribute to elimination of mother-
to-child transmission targets. In this first trial of HIVST 
for index testing, secondary distribution of kits from 
HIV testing clinics reached half (228 [48·1%]) 
of all 474 reported sexual contacts of people with newly 
diagnosed HIV. Study power was limited by low 
prevalence of undiagnosed HIV in Malawi and high 
clinic-level variability. However, additional research is 
Standard care 
group
HIVST only group HIVST plus financial 
incentive group
Women in the ANC cohort and their male partners
Number of eligible women 1447 1465 1632
Number of male partners seen at the 
clinic*
228 (15·8%) NA* 1232 (75·5%)
Mean proportion per cluster, % (SD) 19·7% (7·6) NA 76·5% (20·0)
p value ·· NA <0·0001
Risk difference (95% CI) vs standard 
care
·· NA 56·8% (53·7 to 59·5)
Unadjusted RR (95% CI) 1 (ref) NA 4·51 (3·10 to 6·55)
p value ·· NA <0·0001
Adjusted RR (95% CI)† 1 (ref) NA 2·84 (2·37 to 3·41)
p value ·· NA <0·0001
Number of men circumcised‡ 3 (0·2%) NA 21 (1·3%)
Number of men who started ART 2 (0·1%) 0 22 (1·5%)
Number of men who attended a 
discordant couples’ clinic
NM NM NM
Number of newly diagnosed 
HIV-positive partners seen at the clinic
2 (0·1%) 0 22 (1·5%)
Number of men booked for VMMC 133 (9·2%) NA 211 (12·9%)
Risk difference (95% CI) vs standard 
care
·· NA 3·7% (–6·6 to 24·4)
Patients in the index cohort and their sexual contacts
Number of eligible index patients 234 169 305
Number of sexual contacts tested for 
HIV§
82 (35·0%) 101 (59·8%) 128 (42·0%)
Mean proportion per cluster, % 34·3% 49·7% 51·7%
Risk difference (95% CI) vs standard 
care
·· 15·4% (5·9 to 25·4) 17·4% (9·7 to 25·5)
Unadjusted RR (95% CI) 1 (ref) 1·57 (1·34 to 1·85) 1·45 (1·23 to 1·70)
p value ·· <0·0001 <0·0001
Adjusted RR (95% CI)† 1 (ref) 1·57 (1·22 to 2·02) 1·45 (1·17 to 1·79)
p value ·· <0·0001 <0·0001
Each trial arm had nine clusters. HIVST=HIV self-testing. ANC=antenatal care. RR=risk ratio. NA=not applicable. 
NM=not measured. VMMC=voluntary male medical circumcision. *Measured by clinic attendance with a pre-allocated 
barcoded card. Not measured in the HIVST only group because only individuals with a positive HIVST were encouraged 
to attend the clinic, implying uncertainty in the denominator. †Adjusted for clustering. ‡Using number of men eligible 
for VMMC as the denominator (in part reflects supply-side barriers in accessing VMMC in Malawi). §As reported by the 
index client at their antiretroviral therapy refill visit. 
Table 4: Clinic attendance and VMMC among male partners of women in the ANC cohort and HIV testing 
among sexual contacts of patients in the index cohort
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needed to maximise accuracy from kits distributed by 
partners.
Secondary distribution of HIVST kits for pregnant 
women has consistently outperformed alternative 
approaches with regard to increasing HIV testing, and 
should now be considered regional best practice.4–6 HIV 
incidence during pregnancy and breastfeeding is well 
above rates in women who are not pregnant,18 making 
male partner testing and intensified HIV prevention a 
crucial part of strategies to eliminate mother-to-child 
transmission of HIV.1 To maximise impact from 
strategies based on HIVST, national programmes 
should invest in operational research to monitor and 
optimise the accuracy of secondary distribution of 
HIVST, and to create demand for proven serostatus-
based HIV prevention approaches by the male partner, 
notably prompt ART if HIV-positive19,20 and VMMC if 
HIV-negative.21–23
In this trial, we showed that a conditional financial 
incentive ($10) to retest after HIVST can stimulate 
prompt confirmatory testing, as well as engagement 
with VMMC services in Malawi.4,24–26 Nevertheless, 
incentives are prone to unintended consequences and 
implementation challenges, and might undermine 
sustainability and universal health coverage initiatives.1 
Some women are worried about men using their 
incentive to buy alcohol or transactional sex.11 Failure to 
pass on kits because of this concern might explain the 
less complete follow-up for women from financial 
incentive clinics (1132 [70·1%] of 1615 women recruited) 
compared with women from non-incentivised clinics 
(2246 [78·9%] of 2846), with more pronounced 
differences for the index cohort. Use of non-cash 
incentives might overcome immediate misuse of cash 
incentives. Drawing on experiences of disbursing 
non-cash humanitarian aid and subsidies by govern-
ments in resource-limited settings can overcome 
logistical challenges in implementing incentive-based 
HIV programmes.
This was the first trial of HIVST to enable contact 
tracing and testing for clinic attendees with newly 
diagnosed HIV (ie, index testing). Kits were reportedly 
used by half (229 [48·3%] of 474) of the contacts in the 
index cohort without requiring costly and labour-
intensive home visits.9,27 However, this finding might 
be an underestimate because our analysis assumes 
no uptake by partners of patients who were not re-
interviewed. Index testing is feasible and retains high 
yield, even in settings with low HIV prevalence.9,27
Partners who received the HIVST kit via secondary 
distribution appeared to have some challenges and had 
lower sensitivity (89·7%: 52 true-positive patients and 
six false-negative patients) than did trained providers 
and individuals in previous studies, including those 
who directly received a kit.28 This difference highlights 
the importance of ensuring that secondary distribution 
of HIVST is coupled with sufficient information, such 
as shareable videoclips or other materials, aiming to 
improve this situation by promoting consistently correct 
kit use and supporting interpretation.29
Consistent with previous studies, only four self-
resolving temporary marital separations occurred 
(equating to 0·1% of all participants), with no other 
adverse events reported.4,7
This study had several strengths and novel aspects. 
First, the trial had a cluster-randomised design and 
was large scale, with 27 government clinics as the unit 
of randomisation (including a previously unstudied 
priority patient cohort [index patients]) and ANC clinic 
attendees. This design is key and differs substantially 
from previous studies that were relatively small4 
and individually randomised,5,30,31 or cohort studies,6,32 
which have a huge potential for contamination and bias. 
Second, the interventions were delivered via a pragmatic 
design by Ministry of Health personnel, as would be 
the case during routine implementation (including 
kit supply chain, distribution, and documentation). 
Third, secondary accuracy was investigated, which is a 
key assumption in any secondary distribution study 
or programme. The idea with secondary distribution 
is that the kit is offered indirectly to someone who is 
not present, through a proxy. Until our study, to our 
knowledge, we were not aware of any large study that 
explored secondary accuracy with HIVST kits delivered 
via antenatal care attendees or index patients. Finally, 
financial incentives were used to investigate clinic 
attendance following receipt of HIVST kits by male 
partners of women in the ANC cohort and by sexual 
contacts of patients in the index cohort.
Limitations of this study include statistical power for 
the index cohort outcomes, with Malawi being close to 
HIV elimination targets. Notably, variability between 
clusters was extremely high for the index cohort primary 
outcome of numbers of newly diagnosed HIV-positive 
contacts per clinic (k=0·75). Although we adapted our 
pre-planned analysis to use negative binomial instead of 
Poisson regression, there might still have been residual 
overdispersion affecting confidence intervals. However, a 
probable true effect is supported by the important impact 
of the HIVST plus financial incentive group on male 
partner attendance from ANC clinics. The primary 
ANC cohort outcome (reported male partner testing) and 
equivalent index cohort secondary outcomes were based 
on interview with the kit distributor, not the recipient, 
and are, therefore, prone to reporting bias. There is also 
potential for systematic errors from the rapid HIV test 
kits used and for misclassification of HIVST results due 
to user-reading errors. Furthermore, VMMC outcomes 
in Malawi are limited by supply side issues, requiring a 
minimum of ten men to trigger outreach arrangements 
with a private provider; therefore, only a small proportion 
of men expressing interest in VMMC had surgery.4
Strategies that are better targeted and more efficient at 
testing are needed for HIV programmes to carefully 
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scale back intensity without jeopardising programmatic 
gains.1,10 We have shown that secondary distribution 
of HIVST kits can be readily integrated into routine 
clinic activities, with high uptake by intended users and 
few adverse events. Secondary distribution of HIVST kits 
for pregnant women should now be considered regional 
priority.4–6 Optimising HIVST accuracy, especially in eco-
nomically disadvantaged rural communities, remains an 
important programmatic challenge.29 In any case, novel 
strategies for maintaining HIV services are needed 
during the COVID-19 pan demic, and HIVST-based 
approaches have the major advantage of not requiring 
direct interaction between contacts and pro viders until 
confirmatory testing and enrolment into HIV care. 
HIVST can meet unique programmatic needs and global 
HIV testing targets, both during the COVID-19 pandemic 
and in the long term, and should be implemented 
routinely in all settings with high HIV prevalence.
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